Preventive Nutritional Supplements for Preclinical Conditions (ALPHANUTRI)
Advanced Preventive Nutritional Supplements Targeting Conditions in a Preclinical Phase
The main objective of this intervention study was to evaluate the functionality of a multi-target preparation (rich in phloretin from apple, chromium picolinate, zinc, magnesium and cinnamon extract) on the glucose response of individuals with elevated fasting capillary blood glucose (FCBG) and a risk of developing impaired fasting glucose.
調査の概要
状態
詳細な説明
An interventional study was conducted in collaboration with the Catholic University of San Antonio Murcia (UCAM). A total of 21 volunteers (fasting capillary blood glucose levels >100 mg/dL) who were not taking diabetes medication or antibiotics during the study were recruited. Pregnant or lactating women were also excluded.
The participants were invited to an information session to learn more about the study objectives and procedures, and they signed informed consent forms. During this first visit, anthropometric measurements were taken, and a questionnaire was administered to gather information about their diet and physical activity. Each volunteer made four more visits to the UCAM facilities. On each visit, the volunteers ingested either a placebo capsule or the formulated dietary supplement, followed by a standard breakfast consisting of three toasted bread slices and two single-serving packets of strawberry or peach jam (resulting in a total carbohydrate intake of 49.5 g). The volunteers were randomly assigned to receive the placebo or the supplemet and each of them was taken twice. At time 0 and at different times after breakfast intake (15, 30, 45, 60, 75, 90, 105 and 120 min) blood glucose was measured using capillary blood sample obtained by finger prick and a glucometer.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Murcia、スペイン、30107
- Universidad Católica de San Antonio (UCAM)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Fasting capillary blood glucose (FCBG) values > 100 mg/dL
- To be habitual breakfast consumers
Exclusion Criteria:
- To have diabetes medication during the study
- To have antibiotics during the study
- To be pregnant or in lactating period
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo capsule
Participants receive a matching placebo during their assigned period. |
Capsules with microcrystalline cellulose 102 |
|
実験的:Active Capsules
Participants receive the supplement during their assigned period. |
Capsules with phloretin rich apple extract, magnesium oxide, cinnamon extract, zinc citrate and chromium picolinate |
|
プラセボコンパレーター:Placebo capsule (repetition)
This arm was a repetition of the placebo intake |
Repetition of the placebo (capsules with microcrystalline cellulose 102) intake |
|
実験的:Active capsules (repetition)
This arm was a repetition of the supplement intake |
Repetition of the supplement intake (Capsules with phloretin rich apple extract, magnesium oxide, cinnamon extract, zinc citrate and chromium picolinate) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incremental Area Under the Curve (iAUC) of blood glucose over 120 minutes
時間枠:0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes and 120 minutes following the consumption of breakfast with each capsule
|
Capillary blood glucose was monitored using a glucometer |
0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes and 120 minutes following the consumption of breakfast with each capsule
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Peak Blood Glucose Concentration
時間枠:0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption of the breakfast with each capsule
|
Maximum post-prandial blood glucose concentration (Cmax) during the 120-minute test period. |
0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption of the breakfast with each capsule
|
|
Total area under the curve (AUC)
時間枠:0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption of the breakfast with each capsule
|
Glucose concentration across the 120-minute test period (values down to baseline levels). |
0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption of the breakfast with each capsule
|
|
Blood Glucose Concentration at different times
時間枠:0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption of the breakfast with each capsule
|
Blood glucose concentration at different times post-ingestion |
0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption of the breakfast with each capsule
|
|
Time to peak concentration for glucose
時間枠:0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption the breakfast with each capsule.
|
Time (min) when Cmax of glucose is reached |
0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes following the consumption the breakfast with each capsule.
|
協力者と研究者
捜査官
- 主任研究者:Francisco A Tomás-Barberán, PhD、CEBAS-CSIC
出版物と役立つリンク
一般刊行物
- Costello RB, Dwyer JT, Saldanha L, Bailey RL, Merkel J, Wambogo E. Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review. J Acad Nutr Diet. 2016 Nov;116(11):1794-1802. doi: 10.1016/j.jand.2016.07.015. Epub 2016 Sep 8.
- Lira Neto JCG, Damasceno MMC, Ciol MA, de Freitas RWJF, de Araujo MFM, Teixeira CRS, Carvalho GCN, Lisboa KWSC, Marques RLL, Alencar AMPG, Zanetti ML. Efficacy of Cinnamon as an Adjuvant in Reducing the Glycemic Biomarkers of Type 2 Diabetes Mellitus: A Three-Month, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. J Am Nutr Assoc. 2022 Mar-Apr;41(3):266-274. doi: 10.1080/07315724.2021.1878967. Epub 2021 Feb 19.
- Kostov K. Effects of Magnesium Deficiency on Mechanisms of Insulin Resistance in Type 2 Diabetes: Focusing on the Processes of Insulin Secretion and Signaling. Int J Mol Sci. 2019 Mar 18;20(6):1351. doi: 10.3390/ijms20061351.
- Pelczynska M, Moszak M, Bogdanski P. The Role of Magnesium in the Pathogenesis of Metabolic Disorders. Nutrients. 2022 Apr 20;14(9):1714. doi: 10.3390/nu14091714.
- Ul Hasnain SZ, Ahmed M, Manzoor R, Amin A, Mudassir J, Jafar Rana S, Abbas K. Anti-inflammatory, antidiabetic and hypolipidemic potential of Cinnamomum verum J. Presi bark coupled with FT-IR and HPLC analysis. Pak J Pharm Sci. 2024 Nov-Dec;37(6):1529-1544.
- Zhao F, Pan D, Wang N, Xia H, Zhang H, Wang S, Sun G. Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. Biol Trace Elem Res. 2022 Feb;200(2):516-525. doi: 10.1007/s12011-021-02693-3. Epub 2021 Mar 30.
- Georgaki MN, Tsokkou S, Keramas A, Papamitsou T, Karachrysafi S, Kazakis N. Chromium supplementation and type 2 diabetes mellitus: an extensive systematic review. Environ Geochem Health. 2024 Nov 14;46(12):515. doi: 10.1007/s10653-024-02297-5.
- Derosa G, Maffioli P, D'Angelo A, Foscaldi V, Piazza R, Mangrella M, Fogacci F, Cicero AFG. Exploring nutraceutical solutions for prediabetes: a narrative review on the effects of banaba and chromium picolinate. Eur Rev Med Pharmacol Sci. 2025 Jun;29(6):324-338. doi: 10.26355/eurrev_202506_37275.
- Nakhate KT, Badwaik H, Choudhary R, Sakure K, Agrawal YO, Sharma C, Ojha S, Goyal SN. Therapeutic Potential and Pharmaceutical Development of a Multitargeted Flavonoid Phloretin. Nutrients. 2022 Sep 2;14(17):3638. doi: 10.3390/nu14173638.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CE042501
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。